
|Videos|October 6, 2017
Aggressive Treatment De-Escalation Feasible in HPV-Positive Oropharyngeal Cancer?
Author(s)Daniel J. Ma, MD
This video highlights 2-year results of a phase II study evaluating aggressive adjuvant chemoradiation dose de-escalation in HPV-positive oropharynx squamous cell carcinoma.
Advertisement
In this video, Daniel J. Ma, MD, of the Mayo Clinic in Rochester, Minnesota, discusses 2-year results of a phase II study evaluating aggressive adjuvant chemoradiation dose de-escalation in HPV-positive oropharynx squamous cell carcinoma.
Ma presented results of the study (
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Epcoritamab Combo Shows Sustained Remissions in Follicular Lymphoma
2
Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer
3
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
4
GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology
5





















































